Positive new and updated data from a phase I and pivotal phase II trial (ELM-1 and ELM-2), evaluating investigational odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, were presented in an oral session at the 64th American Society of Hematology Annual Meeting and Exposition and will form the basis of planned submissions to regulatory authorities in 2023, including to FDA.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.
